Press Release: Triplet Therapeutics : Triplet Therapeutics Presents Preclinical Data for TTX-3360, Announces Equity Pledge at the CHDI Foundation's 16th Annual HD Therapeutics Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today presented preclinical data in Huntington's disease (HD) for its first clinical candidate TTX-3360, including the therapeutic target and route of administration, in a virtual presentation at the CHDI Foundation's 16th Annual HD Therapeutics Conference. Also in the presentation, Triplet underscored its long-term commitment t